Genecast’s business faces different challenges as NGS hasn't developed as rigid demand. It's difficult for Genecast to make profits in the short term. Valuation performance after IPO is also a concern
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.